Chemesis International Inc. - günstige Cannabis-Aktie (Seite 101)
eröffnet am 05.09.18 16:13:54 von
neuester Beitrag 06.03.24 18:33:05 von
neuester Beitrag 06.03.24 18:33:05 von
Beiträge: 2.751
ID: 1.287.816
ID: 1.287.816
Aufrufe heute: 0
Gesamt: 352.613
Gesamt: 352.613
Aktive User: 0
ISIN: CA75867L2066 · WKN: A407GC · Symbol: RUU
0,0950
CAD
+5,56 %
+0,0050 CAD
Letzter Kurs 22.04.24 CSE
Neuigkeiten
01.03.24 · globenewswire  |
27.02.24 · globenewswire |
10.02.24 · globenewswire |
08.02.24 · globenewswire |
Werte aus der Branche Rohstoffe
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7950 | +30,33 | |
| 227,00 | +21,91 | |
| 5,1500 | +21,75 | |
| 29,98 | +18,24 | |
| 16,050 | +17,41 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6850 | -6,80 | |
| 29,70 | -7,19 | |
| 0,8800 | -7,37 | |
| 0,5400 | -8,47 | |
| 46,59 | -98,01 |
Beitrag zu dieser Diskussion schreiben
Feedback
„...approximately $75,000,000 USD for the 2020 calender year...“ hört sich jetzt nicht so wenig an, für ein Unternehmen, das gerade mal $100,000,000 USD Marktkapitalisierung hat.
Der Kurs wird so lange nicht signifikant steigen so lange die Shorts ihr Unwesen treiben oder das Unternehmen mal wirklich eine HammerNews zu vermelden hat, da helfen Meldungen für ein paar Millionen nicht aus.
Woran liegt es, dass der Kurs bei jeder Nachricht fällt? Die letzte Nachricht sichert Chemesis einen Umsatz von mehreren Millionen für 2020. Was muss denn noch alles kommen, dass der Kurs signifikant steigt?
Super geil mal wieder 💩
Für den ein oder anderen der noch nicht so lange dabei ist, was aktuelles zum Lesen
https://equity.guru/2019/08/05/chemesis-csi-c-smacks-another…
https://equity.guru/2019/08/05/chemesis-csi-c-smacks-another…
Trading Spotlight
In Kanada ist heute mal wieder ein Feiertag, daher kein Handel. Aber immerhin ist an der OTC Handel. https://www.stockwatch.com/Quote/Detail.aspx?symbol=CADMF&re… Dort ist die Aktie (knapp) im grünen Bereich.
Antwort auf Beitrag Nr.: 61.173.798 von Dennis86 am 05.08.19 10:02:32
Ja, die Prognose ist fast identisch. Da waren es 78,9 Mio.
Das jetzt eine Zahl genannt wird, die geringfügig niedriger ist, finde ich nicht tragisch. Da die letzte Präsentation schon aus dem März 2019 ist. Jetzt ist man also ein halbes Jahr schlauer. Zudem kann sich die Prognose ja auch ganz schnell wieder mal ändern. Wenn CSI die von uns erhoffte richtig große Großbestellung erhält.
P.S. Auch wenn es uns nicht direkt betrifft. Aber Rapid Dose (QuickStrip) hat einen Aufrag i.H.v. 4 Mio. erhalten (... with Ukraine Pharma). Früher oder später rechne ich auch mit einer ersten Bestellung für Kalifornien oder Puerto Rico. Auch wenn dies natürlich noch etwas dauern könnte. Ich halte es für möglich, dass man den einen oder anderen bereits kostenlos ein paar Proben zu Testzwecken übergeben hat. Aber das ist alles erstmal nur eine Spekulation meinerseits.
Zitat von Dennis86: @Tzadoz: wie hoch war die Summe in der letzten Präsentation für das Jahr 2020 gewesen?
Wenn ich mich richtig erinnern kann, dann war sie in ähnlicher Höhe wie jetzt mitgeteilt.
Ja, die Prognose ist fast identisch. Da waren es 78,9 Mio.
Das jetzt eine Zahl genannt wird, die geringfügig niedriger ist, finde ich nicht tragisch. Da die letzte Präsentation schon aus dem März 2019 ist. Jetzt ist man also ein halbes Jahr schlauer. Zudem kann sich die Prognose ja auch ganz schnell wieder mal ändern. Wenn CSI die von uns erhoffte richtig große Großbestellung erhält.
P.S. Auch wenn es uns nicht direkt betrifft. Aber Rapid Dose (QuickStrip) hat einen Aufrag i.H.v. 4 Mio. erhalten (... with Ukraine Pharma). Früher oder später rechne ich auch mit einer ersten Bestellung für Kalifornien oder Puerto Rico. Auch wenn dies natürlich noch etwas dauern könnte. Ich halte es für möglich, dass man den einen oder anderen bereits kostenlos ein paar Proben zu Testzwecken übergeben hat. Aber das ist alles erstmal nur eine Spekulation meinerseits.
Antwort auf Beitrag Nr.: 61.173.798 von Dennis86 am 05.08.19 10:02:32Laut der Präsentation war für das Fiskaljahr 2020 (endet am 30.06.2020) ein Umsatz von 78,9 Mio. USD prognostiziert. Umgerechnet sind es 104,4 Mio. CAD.
Antwort auf Beitrag Nr.: 61.173.435 von tzadoz2014 am 05.08.19 09:30:53Sehe ich genau so, es war eine logische Folgerung dessen, was sie schon länger verfolgt haben.
An der nunmehr mitgeteilten Umsatzsumme müssen sie sich jetzt messen lassen.
@Tzadoz: wie hoch war die Summe in der letzten Präsentation für das Jahr 2020 gewesen?
Wenn ich mich richtig erinnern kann, dann war sie in ähnlicher Höhe wie jetzt mitgeteilt.
Mal gespannt wie diese News in Kanada aufgenommen wird, insgesamt dürfte es aber wieder über 1€ laufen.
An der nunmehr mitgeteilten Umsatzsumme müssen sie sich jetzt messen lassen.
@Tzadoz: wie hoch war die Summe in der letzten Präsentation für das Jahr 2020 gewesen?
Wenn ich mich richtig erinnern kann, dann war sie in ähnlicher Höhe wie jetzt mitgeteilt.
Mal gespannt wie diese News in Kanada aufgenommen wird, insgesamt dürfte es aber wieder über 1€ laufen.
Die Meldung kommt für mich NICHT überraschend. Ich hatte früher oder später damit gerechnet, dass man sich die Mehrheit der Anteile schnappt. Damit wird man in Puerto Rico vielleicht sogar DER Big-Player. Das weiß ich aber nicht. Zudem ist GSRX ja nicht nur in Puerto Rico aktiv. Auch in Nordamerika macht man so einen großen Schritt nach vorne. Da man jetzt nicht nur Hersteller ist. Sondern auch selbst Läden betreibt.
Einen wichtigen Teil in den News habe ich mal "Fett" bzw. "Rot" markiert.
https://web.tmxmoney.com/article.php?newsid=5362835214305362…
VANCOUVER, British Columbia, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), announces that it has entered into binding share exchange agreements (the “Share Exchange Agreements”) with certain shareholders (“Selling Shareholders”) of GSRX Industries Inc. (“GSRX”) (OTCQB: GSRX) (the “Acquisition”), pursuant to which the Company will acquire an aggregate of 42,634,124 common shares and 1,000 preferred shares of GSRX, in exchange for an aggregate of 18,915,738 Chemesis common shares to be issued to the Selling Shareholders (“Chemesis Consideration Shares”). Together with the GSRX common shares already held by the Company, completion of the Acquisition will result in the Company holding an aggregate of 54,301,122 common shares and 1,000 preferred shares of GSRX. The preferred shares carry, in aggregate, 51% of all outstanding share voting rights of GSRX. Accordingly, upon completion of the Acquisition, the Company will hold an aggregate 66.29% of all outstanding share voting rights. The Chemesis Consideration Shares shall be subject to a 36-month leak out schedule.
The Company has retained INFOR Financial Inc. as a financial advisor with respect to the Acquisition. Completion of the Acquisition is expected to occur prior to August 31, 2019.
Upon acquiring a controlling interest in GSRX pursuant to the Acquisition, Chemesis will effectively be a fully vertically-integrated, multi-state operator with assets in six states which includes California, Tennessee, Arizona, Michigan, Texas, and Puerto Rico, with significantly-enhanced consolidated gross revenue projections, estimated to be approximately $75,000,000 USD for the 2020 calendar year (on a fully consolidated basis) (“Estimated Revenue Projection”).
The Company has extensive manufacturing, extraction, distribution, and processing capabilities, which complement and build upon GSRX’s proven ability to professionally operate cannabis dispensaries. Chemesis intends to leverage its facilities and processing capabilities to manufacture finished goods for GSRX’s operating dispensaries, with the aim of further increasing margins and operational efficiencies.
GSRX’s asset portfolio includes:
Five operational dispensaries in Puerto Rico, which operate under Green Spirit Rx brand with locations in Dorado, Carolina, Hato Rey, Fajardo and San Juan.
An additional five pre-qualified dispensaries in Puerto Rico with locations in large tourist centres and dense populations. Each dispensary is in various stages of development and construction.
A fully licensed cannabis distribution centre in Point Arena, California. The distribution centre is expected to service over 400 dispensaries in Northern & Central California.
The Green Room, a boutique dispensary located in Point Arena California that has been owned and operated since April 2018.
The Green Room, a 4,500 ft2 large scale dispensary located in Palm Springs, California. The dispensary is currently undergoing renovations and expects to open by calendar Q1 2020. With over 10 million annual visitors, Palm Springs has become one of the most popular destination cites in California for tourists all over the world.
Retail CBD stores in Texas and Tennessee, including Nashville, with products such as creams, balms, tinctures, pet products, face masks, vape pens, and soft gels.
In addition, GSRX has recently submitted a comprehensive business plan to the City of Riverbank, California, which constitutes phase one of its application for a retail location there and GSRX has also entered into a long-term lease with a landlord for 2600 square feet of building space there. Approximately 1 million residents in the surrounding communities are expected to help secure a strong customer base for both medical and adult use cannabis products.
“GSRX has built an incredibly strong portfolio of retail and manufacturing assets and the company is realizing growth in all aspects of its operations,” stated Chief Executive Officer of Chemesis, Edgar Montero. The Company is incredibly excited about this acquisition and believes it will be highly accretive in terms of the potential to realize efficiencies and complement the strengths of each company’s respective business lines.”
The Company notes that the Estimated Revenue Projection is provided in order to furnish readers with information as to the potential revenue generation potential of the Company and GSRX on a consolidated basis, as the same was an important consideration for the Company in pursuing the Acquisition and in arriving at a value for the GSRX shares being acquired. While the Company believes that the assumptions on which the Estimated Revenue Projection are based are reasonable in the circumstances, readers are reminded that the information is forward-looking in nature, and, therefore, inherently subject to uncertainty, and that such information may not be appropriate for other purposes.
This news release does not constitute an offer to sell or the solicitation of an offer to purchase any securities. The securities referenced herein may not be offered sold in the United States absent registration under the U.S. Securities Act of 1933, as amended, or an exemption therefore.
Einen wichtigen Teil in den News habe ich mal "Fett" bzw. "Rot" markiert.
https://web.tmxmoney.com/article.php?newsid=5362835214305362…
VANCOUVER, British Columbia, Aug. 05, 2019 (GLOBE NEWSWIRE) -- Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), announces that it has entered into binding share exchange agreements (the “Share Exchange Agreements”) with certain shareholders (“Selling Shareholders”) of GSRX Industries Inc. (“GSRX”) (OTCQB: GSRX) (the “Acquisition”), pursuant to which the Company will acquire an aggregate of 42,634,124 common shares and 1,000 preferred shares of GSRX, in exchange for an aggregate of 18,915,738 Chemesis common shares to be issued to the Selling Shareholders (“Chemesis Consideration Shares”). Together with the GSRX common shares already held by the Company, completion of the Acquisition will result in the Company holding an aggregate of 54,301,122 common shares and 1,000 preferred shares of GSRX. The preferred shares carry, in aggregate, 51% of all outstanding share voting rights of GSRX. Accordingly, upon completion of the Acquisition, the Company will hold an aggregate 66.29% of all outstanding share voting rights. The Chemesis Consideration Shares shall be subject to a 36-month leak out schedule.
The Company has retained INFOR Financial Inc. as a financial advisor with respect to the Acquisition. Completion of the Acquisition is expected to occur prior to August 31, 2019.
Upon acquiring a controlling interest in GSRX pursuant to the Acquisition, Chemesis will effectively be a fully vertically-integrated, multi-state operator with assets in six states which includes California, Tennessee, Arizona, Michigan, Texas, and Puerto Rico, with significantly-enhanced consolidated gross revenue projections, estimated to be approximately $75,000,000 USD for the 2020 calendar year (on a fully consolidated basis) (“Estimated Revenue Projection”).
The Company has extensive manufacturing, extraction, distribution, and processing capabilities, which complement and build upon GSRX’s proven ability to professionally operate cannabis dispensaries. Chemesis intends to leverage its facilities and processing capabilities to manufacture finished goods for GSRX’s operating dispensaries, with the aim of further increasing margins and operational efficiencies.
GSRX’s asset portfolio includes:
Five operational dispensaries in Puerto Rico, which operate under Green Spirit Rx brand with locations in Dorado, Carolina, Hato Rey, Fajardo and San Juan.
An additional five pre-qualified dispensaries in Puerto Rico with locations in large tourist centres and dense populations. Each dispensary is in various stages of development and construction.
A fully licensed cannabis distribution centre in Point Arena, California. The distribution centre is expected to service over 400 dispensaries in Northern & Central California.
The Green Room, a boutique dispensary located in Point Arena California that has been owned and operated since April 2018.
The Green Room, a 4,500 ft2 large scale dispensary located in Palm Springs, California. The dispensary is currently undergoing renovations and expects to open by calendar Q1 2020. With over 10 million annual visitors, Palm Springs has become one of the most popular destination cites in California for tourists all over the world.
Retail CBD stores in Texas and Tennessee, including Nashville, with products such as creams, balms, tinctures, pet products, face masks, vape pens, and soft gels.
In addition, GSRX has recently submitted a comprehensive business plan to the City of Riverbank, California, which constitutes phase one of its application for a retail location there and GSRX has also entered into a long-term lease with a landlord for 2600 square feet of building space there. Approximately 1 million residents in the surrounding communities are expected to help secure a strong customer base for both medical and adult use cannabis products.
“GSRX has built an incredibly strong portfolio of retail and manufacturing assets and the company is realizing growth in all aspects of its operations,” stated Chief Executive Officer of Chemesis, Edgar Montero. The Company is incredibly excited about this acquisition and believes it will be highly accretive in terms of the potential to realize efficiencies and complement the strengths of each company’s respective business lines.”
The Company notes that the Estimated Revenue Projection is provided in order to furnish readers with information as to the potential revenue generation potential of the Company and GSRX on a consolidated basis, as the same was an important consideration for the Company in pursuing the Acquisition and in arriving at a value for the GSRX shares being acquired. While the Company believes that the assumptions on which the Estimated Revenue Projection are based are reasonable in the circumstances, readers are reminded that the information is forward-looking in nature, and, therefore, inherently subject to uncertainty, and that such information may not be appropriate for other purposes.
This news release does not constitute an offer to sell or the solicitation of an offer to purchase any securities. The securities referenced herein may not be offered sold in the United States absent registration under the U.S. Securities Act of 1933, as amended, or an exemption therefore.
Durchsuchen
Chemesis International Inc. - günstige Cannabis-Aktie
